Starting May 14th, 2021, the data in will be frozen in preparation for the migration to the new Primo VE-powered LocatorPlus Catalog which goes live June 8th, 2021. See the Technical Bulletin article for more information. will remain available until August 31st, 2021.

Start Over
Detailed View
SearchTitlesLibrary InformationOther DatabasesHelpHome

Collections of the National Library of Medicine
Search Request: Simple Search = 101773043
Search Results: Displaying 1 of 1 records

Summary ViewDetailed ViewTable of ContentsMARC ViewMore Like This

HEAL Workshop : Target Validation for Non-addictive Therapeutics...

Title: HEAL Workshop : Target Validation for Non-addictive Therapeutics Development for Pain / National Institute of Neurological Disorders and Stroke, NIH.
Conference(s): HEAL Workshop: Target Validation for Non-addictive Therapeutics Development for Pain (2020 : Online), author.
Publisher: [Bethesda, Md.] : [National Institutes of Health], [2020]
Related Names: National Institute of Neurological Disorders and Stroke (U.S.), issuing body.
Description: 1 online resource (2 streaming video file (8 hr., 39 min.)) : color, sound
Content Type: two-dimensional moving image
Media Type: computer
Carrier Type: online resource
Language: eng
Electronic Links:
MeSH Subjects: Pain --drug therapy
Analgesics --therapeutic use
Behavior, Addictive --prevention & control
Molecular Targeted Therapy
Drug Discovery
Summary: (CIT): Despite advances in the understanding of pain physiology there has been a paucity of novel analgesic medications developed to address the still high unmet need of pain patients especially those who rely on addictive opioid medicines for pain relief. The successful development of novel non-opioid, non-addictive therapeutics requires advances in preclinical target validation that demonstrate sufficient human disease relevance to trigger investment in non-clinical development and subsequent clinical trials to obtain proof of biology and early proof of efficacy before registrational studies. Translating novel target discoveries to the clinic depends on the quality of target validation and the rigorous implementation of research operating plans to provide compelling data supporting a causative link between the modulation of molecular target(s) and a disease phenotype associated with the disease state. The full target validation process covers target identification to proof-of concept efficacy in human subjects in clinical trials. This workshop will focus on the key preclinical experimental validation package components that de-risk and provide rigorous rationale for the pursuit of novel targets with minimal side effects and a reduced potential of abuse/addiction liability. The focus will be on the stage appropriate data required to justify further preclinical and clinical therapeutics development activities across the translational spectrum.
Notes: Closed-captioned.
NLM Unique ID: 101773043
Other ID Numbers: (DNLM)CIT:30348


Options for Print, Save or E-mail
Select Download Format:
E-mail Full record(s) to:

SearchTitlesLibrary InformationOther DatabasesHelpHome

Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services
Contact NLM